Victoria Harris

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Christopher Butler, Richard Hobbs, Oghenekome Gbinigie et al. · The Lancet · 2022 · 406 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +7

Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial

Celina Jin, Malick M. Gibani, Maria Moore et al. · The Lancet · 2017 · 318 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Christopher Butler, Jienchi Dorward, Ly‐Mee Yu et al. · The Lancet · 2021 · 318 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Ly‐Mee Yu, Mona Bafadhel, Jienchi Dorward et al. · The Lancet · 2021 · 310 citations · Full text

Pharmacy, Community Medicine, Pharmacotherapy +14

Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial

Daniel Freeman, Bao Sheng Loe, Ly‐Mee Yu et al. · The Lancet Public Health · 2021 · 288 citations · Full text

Veterinary Medicine, Infectious Diseases, Preventive Medicine +16